Pirlindole

Pirlindole
Clinical data
Trade namesPirazidol
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability20–30%
Protein binding95%
Metabolismhepatic
Onset of action2 to 8 hours
Elimination half-life2.1 hours [1]
Excretionurine (50–70%), feces (25–45%)
Identifiers
IUPAC name
  • 8-methyl-2,3,3a,4,5,6-hexahydro-1H-pyrazino[3,2,1-jk]carbazole
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H18N2
Molar mass226.323 g·mol−1
3D model (JSmol)
SMILES
  • CC1=CC2=C(C=C1)N3CCNC4C3=C2CCC4

Pirlindole (Lifril, Pyrazidol) is a reversible inhibitor of monoamine oxidase A (RIMA) which was developed and is used in Russia as an antidepressant.[2]:337 It is structurally and pharmacologically related to metralindole.

See also

References

  1. Pöldinger W (1985). "Pirlindole: results of an open clinical study in out-patients and of a double-blind study against maprotiline.". Psychiatry the State of the Art. Boston, MA.: Springer. pp. 283–289. doi:10.1007/978-1-4613-2363-1_44. ISBN 978-1-4613-2363-1.
  2. Medvedev AE, Shvedov VI, Chulkova TM, Fedotova OA, Saederup E, Squires RF (1998). Finberg JP, Youdim MB, Riederer P, Tipton KF (eds.). "The influence of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase A and GABAA receptor binding". Journal of Neural Transmission. Journal of Neural Transmission. Supplement. 52 (Supplementum): 337–42. doi:10.1007/978-3-7091-6499-0_36. ISBN 978-3211830376. PMID 9564636.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.